Stockreport

Northland Highlights ARS Pharmaceuticals, Inc. (SPRY) Needle-Free Therapy as Major Innovation Driver [Yahoo! Finance]

ARS Pharmaceuticals, Inc.  (SPRY) 
PDF TheFly reported on April 9 that Northland initiated coverage of SPRY with an Outperform rating and a $25 price target. The firm highlighted Neffy, a needle-free intrana [Read more]